Granulomatous and lichenoid Dermatitis after IgG4 anti-PD-1 Monoclonal Antibody Therapy for Advanced Cancer

Nivolumab is a fully human IgG4 monoclonal antibody directed against programmed cell death protein 1 (PD-1). PD-1 inhibition allows T-cell activation and recruitment to destroy cancer cells. Checkpoint inhibitors have shown significant survival advantage and relatively low side effects in comparison with conventional chemotherapy in several types of advanced cancer. Granulomatous cutaneous reactions have been reported showing sarcoidal and panniculitic morphology. Here we present a case of drug-induced lichenoid and granulomatous dermatitis after checkpoint inhibitor therapy observed in a 63-year-old male treated with nivolumab for advanced glioblastoma. This morphology has not been previously reported. We documented a high number of CD8+ T cells within the lesions. Additionally, we review the side effects observed with the use of checkpoint inhibitors with special focus on cutaneous manifestations.

http://ift.tt/2GzcZCn